These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23294701)

  • 21. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats.
    Dansereau MA; Gosselin RD; Pohl M; Pommier B; Mechighel P; Mauborgne A; Rostene W; Kitabgi P; Beaudet N; Sarret P; Melik-Parsadaniantz S
    J Neurochem; 2008 Jul; 106(2):757-69. PubMed ID: 18419759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The discovery of novel cyclohexylamide CCR2 antagonists.
    Lanter JC; Markotan TP; Zhang X; Subasinghe N; Kang FA; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Molloy CJ; Sui Z
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7496-501. PubMed ID: 22061641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).
    Carter PH; Brown GD; Friedrich SR; Cherney RJ; Tebben AJ; Lo YC; Yang G; Jezak H; Solomon KA; Scherle PA; Decicco CP
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5455-61. PubMed ID: 17720492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspergillus antigen induces robust Th2 cytokine production, inflammation, airway hyperreactivity and fibrosis in the absence of MCP-1 or CCR2.
    Koth LL; Rodriguez MW; Bernstein XL; Chan S; Huang X; Charo IF; Rollins BJ; Erle DJ
    Respir Res; 2004 Sep; 5(1):12. PubMed ID: 15377395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor.
    Doyon J; Coesemans E; Boeckx S; Buntinx M; Hermans B; Van Wauwe JP; Gilissen RA; De Groot AH; Corens D; Van Lommen G
    ChemMedChem; 2008 Apr; 3(4):660-9. PubMed ID: 18188859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCR2 receptor ligands inhibit Cav3.2 T-type calcium channels.
    You H; Altier C; Zamponi GW
    Mol Pharmacol; 2010 Feb; 77(2):211-7. PubMed ID: 19864434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists.
    Vilums M; Zweemer AJ; Yu Z; de Vries H; Hillger JM; Wapenaar H; Bollen IA; Barmare F; Gross R; Clemens J; Krenitsky P; Brussee J; Stamos D; Saunders J; Heitman LH; Ijzerman AP
    J Med Chem; 2013 Oct; 56(19):7706-14. PubMed ID: 24028535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy.
    Qin LH; Wang ZL; Xie X; Long YQ
    Bioorg Med Chem; 2018 Jul; 26(12):3559-3572. PubMed ID: 29805075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.
    Hall SE; Mao A; Nicolaidou V; Finelli M; Wise EL; Nedjai B; Kanjanapangka J; Harirchian P; Chen D; Selchau V; Ribeiro S; Schyler S; Pease JE; Horuk R; Vaidehi N
    Mol Pharmacol; 2009 Jun; 75(6):1325-36. PubMed ID: 19297521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo.
    Han KH; Ryu J; Hong KH; Ko J; Pak YK; Kim JB; Park SW; Kim JJ
    Circulation; 2005 Mar; 111(11):1439-47. PubMed ID: 15781755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis.
    Rafei M; Berchiche YA; Birman E; Boivin MN; Young YK; Wu JH; Heveker N; Galipeau J
    J Immunol; 2009 Aug; 183(3):1759-66. PubMed ID: 19592643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells.
    Chiu HY; Sun KH; Chen SY; Wang HH; Lee MY; Tsou YC; Jwo SC; Sun GH; Tang SJ
    Cytokine; 2012 Aug; 59(2):423-32. PubMed ID: 22617682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models.
    Hogaboam CM; Bone-Larson CL; Lipinski S; Lukacs NW; Chensue SW; Strieter RM; Kunkel SL
    J Immunol; 1999 Aug; 163(4):2193-201. PubMed ID: 10438961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2.
    Abbadie C; Lindia JA; Cumiskey AM; Peterson LB; Mudgett JS; Bayne EK; DeMartino JA; MacIntyre DE; Forrest MJ
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7947-52. PubMed ID: 12808141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones.
    Gosselin RD; Varela C; Banisadr G; Mechighel P; Rostene W; Kitabgi P; Melik-Parsadaniantz S
    J Neurochem; 2005 Nov; 95(4):1023-34. PubMed ID: 16150057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists.
    Vilums M; Zweemer AJ; Barmare F; van der Gracht AM; Bleeker DC; Yu Z; de Vries H; Gross R; Clemens J; Krenitsky P; Brussee J; Stamos D; Saunders J; Heitman LH; IJzerman AP
    Eur J Med Chem; 2015 Mar; 93():121-34. PubMed ID: 25666912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
    Cherney RJ; Brogan JB; Mo R; Lo YC; Yang G; Miller PB; Scherle PA; Molino BF; Carter PH; Decicco CP
    Bioorg Med Chem Lett; 2009 Feb; 19(3):597-601. PubMed ID: 19131247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.
    Schober A; Zernecke A; Liehn EA; von Hundelshausen P; Knarren S; Kuziel WA; Weber C
    Circ Res; 2004 Nov; 95(11):1125-33. PubMed ID: 15528472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational design of CCR2 antagonists: a survey of computational studies.
    Sobhia ME; Singh R; Kare P; Chavan S
    Expert Opin Drug Discov; 2010 Jun; 5(6):543-57. PubMed ID: 22823166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice.
    Maus U; von Grote K; Kuziel WA; Mack M; Miller EJ; Cihak J; Stangassinger M; Maus R; Schlöndorff D; Seeger W; Lohmeyer J
    Am J Respir Crit Care Med; 2002 Aug; 166(3):268-73. PubMed ID: 12153956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.